Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials

NCT ID NCT05985655

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 participants will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma fallopian tube cancer fallopian tube neoplasm fallopian tube serous adenocarcinoma head and neck squamous cell carcinoma hormone receptor-positive breast cancer non-small cell lung carcinoma ovarian carcinoma ovarian serous adenocarcinoma pancreatic adenocarcinoma primary peritoneal carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BREAST CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) HORMONE RECEPTOR POSITIVE [HR+] AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE [HER2-] BREAST CARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC ADENOCARCINOMA PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • CHU Sart Tilman

    RECRUITING

    Liège, Belgium

  • Clinique Universitaires Saint-Luc

    RECRUITING

    Brussels, Belgium

  • GZA Ziekenhuizen - Campus Sint-Augustinus

    RECRUITING

    Antwerp, Belgium

  • Institute Jules Bordet

    RECRUITING

    Brussels, Belgium

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Newcastle Upon Tyne NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, United Kingdom

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

  • START San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • The Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, United Kingdom

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UCL Hospitals NHS Foundation Trust

    RECRUITING

    London, United Kingdom

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.